We are currently developing small molecules with antineoplastic and anti-inflammatory properties.
Most of our compounds (read more) are chemically-modified already approved drugs. Our products demonstrate a large therapeutic window and negligible toxicity.
Meanwhile, our pipeline includes a number of modified NSAIDs and other compounds.
For example, OXT-328, a derivative of the nonsteroidal anti-inflammatory drug (NSAID) sulindac, displays in numerous preclinical models superior efficacy and safety compared to conventional sulindac.
Key to these properties is the type of their proprietary chemical modification and the resultant novel mechanism of action, very different from that of the parent compound.